Papers

Peer-reviewed Corresponding author
Jul, 2005

Dopamine agonist pergolide prevents levodopa-induced quinoprotein formation in Parkinsonian striatum and shows quenching effects on dopamine-semiquinone generated in vitro

Clinical Neuropharmacology
  • Ikuko Miyazaki
  • ,
  • Masato Asanuma
  • ,
  • Francisco J. Diaz-Corrales
  • ,
  • Ko Miyoshi
  • ,
  • Norio Ogawa

Volume
28
Number
4
First page
155
Last page
160
Language
English
Publishing type
Research paper (scientific journal)
DOI
10.1097/01.wnf.0000175523.33334.24

The neurotoxicity of dopamine (DA) quinones that appears in dopaminergic neuron-specific oxidative stress has recently been shown to play a role in the pathogenesis and/or progression of Parkinson disease. To clarify the effects of a DA agonist, pergolide, on the levodopa-induced elevation of quinones, the authors examined, striatal changes in quinoprotein using a hemi-parkinsonian mouse model. The level of striatal quinoprotein was significantly elevated specifically on the parkinsonian side, but not on the control side, after repeated levodopa administration. This levodopa-induced increase in striatal quinoprotein was almost completely suppressed by adjunctive administration with pergolide on the lesioned side. Furthermore, it was clarified that pergolide scavenged DA-semiquinones generated in vitro in a dose-dependent manner. These suppressive and quenching effects of pergolide against cytotoxic DA quinones may play a key role in its neuroprotective mechanism in the parkinsonian brain. Copyright © 2005 by Lippincott Williams &amp
Wilkins.

Link information
DOI
https://doi.org/10.1097/01.wnf.0000175523.33334.24
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/16062092
ID information
  • DOI : 10.1097/01.wnf.0000175523.33334.24
  • ISSN : 0362-5664
  • Pubmed ID : 16062092
  • SCOPUS ID : 23644452346

Export
BibTeX RIS